PDC Biotech's Series A Round

PDC Biotech raised a round of funding on November 16, 2009.

PDC Biotech is developing a compound, PDC31 which is being developed for the treatment of preterm labor and primary dysmenorrhea. PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor,…

Articles about PDC Biotech's Series A Round: